Document is current
Any future updates will be listed below
-
Authors
Tsimberidou, Apostolia Maria
Grothey, Axel
Sigal, Darren
Lenz, Heinz-Josef
Hochster, Howard S.
Chao, Yee
Bai, Li-Yuan
Yen, Chia-Jui L.
Xu, Dong
Saville, M. Wayne
-
Funding
Funding for this research was provided by:
NIH National Cancer Institute (P30 CA016672)
OBI Pharma, Inc.
- License Information
-
More Information
Article History
Received: 18 June 2024
Accepted: 29 August 2024
First Online: 23 September 2024
Declarations
:
: Apostolia Maria Tsimberidou: Clinical Trial Research Funding (received through the institution): OBI Pharma, Agenus, Vividion, Macrogenics, AbbVie, IMMATICS, Novocure, Tachyon, Parker Institute for Cancer Immunotherapy, Tempus, and Tvardi; fees for consulting or advisory roles for Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, Macrogenics, NEX-I, and VinceRx. Dong Xu and M. Wayne Saville are employees of OBI Pharma USA, Inc. The remaining authors declare no relevant conflict of interest.
